Fiera Capital Corp Lowers Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Fiera Capital Corp decreased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 58,036 shares of the biotechnology company’s stock after selling 1,022 shares during the quarter. Fiera Capital Corp owned approximately 0.05% of Arrowhead Pharmaceuticals worth $1,776,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC bought a new position in Arrowhead Pharmaceuticals during the 4th quarter worth about $309,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Arrowhead Pharmaceuticals by 12.3% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,714 shares of the biotechnology company’s stock valued at $279,000 after purchasing an additional 952 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Arrowhead Pharmaceuticals by 13.6% during the fourth quarter. BNP Paribas Financial Markets now owns 243,605 shares of the biotechnology company’s stock valued at $7,454,000 after buying an additional 29,124 shares during the period. E Fund Management Co. Ltd. raised its stake in Arrowhead Pharmaceuticals by 27.7% in the fourth quarter. E Fund Management Co. Ltd. now owns 19,531 shares of the biotechnology company’s stock worth $598,000 after buying an additional 4,238 shares in the last quarter. Finally, Van ECK Associates Corp lifted its holdings in Arrowhead Pharmaceuticals by 22.9% during the fourth quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company’s stock worth $73,000 after buying an additional 447 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Citigroup increased their target price on Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the company a “neutral” rating in a research report on Wednesday, February 7th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, May 10th. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, May 13th. Morgan Stanley reduced their price objective on shares of Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating for the company in a research note on Monday, May 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $50.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $51.00.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the sale, the director now owns 30,205 shares of the company’s stock, valued at approximately $704,078.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CFO Kenneth Allen Myszkowski sold 40,000 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $35.19, for a total transaction of $1,407,600.00. Following the completion of the transaction, the chief financial officer now owns 400,600 shares of the company’s stock, valued at $14,097,114. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Victoria Vakiener sold 1,799 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the transaction, the director now owns 30,205 shares of the company’s stock, valued at $704,078.55. The disclosure for this sale can be found here. 4.50% of the stock is owned by insiders.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $24.77 on Friday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $20.67 and a twelve month high of $39.83. The company’s 50 day moving average is $25.47 and its two-hundred day moving average is $28.67.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. The company’s revenue was down 100.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.45 EPS. As a group, research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.92 earnings per share for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.